Article Detail - JE Part B
MolDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, and Neoplasia - Published for Review and Comments
This proposed Local Coverage Determination (LCD) has been published for review and comments for contract numbers: 01112 (NCA), 01182 (SCA), 01212 (AS, GU, HI, and NMI), and 01312 (NV).
Medicare Coverage Database (MCD) Number: DL396262/DA59032
LCD Title: MolDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, and Neoplasia
LCA Title: Billing and Coding: MolDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, and Neoplasia
Comment period: April 28, 2022 - June 11, 2022
Visit the CMS MCD to access Proposed LCDs not released to final LCDs.
Providers may address details for comment submission for this policy. When sending comments, reference the specific policy to which they are related. See the Proposed LCDs webpage for email and mail specifics.